InvestorsHub Logo
Followers 122
Posts 43770
Boards Moderated 1
Alias Born 09/06/2012

Re: None

Monday, 03/05/2018 12:30:53 PM

Monday, March 05, 2018 12:30:53 PM

Post# of 2432
The SEC investigation of Vitality Biopharma Inc (VBIO) continues



Form 10Q filed with SEC Feb 14, 2018


https://www.sec.gov/Archives/edgar/data/1438943/000149315218002127/form10-q.htm

7. LEGAL AND OTHER PROCEEDINGS


On August 19, 2016, we filed a resale registration statement on Form S-1 (“Form S-1”) with the SEC to register 2,650,000 shares of our common stock and 7,950,000 shares of our common stock issuable upon exercise of certain warrants. We received a letter from the Washington D.C. office of the SEC dated December 10, 2016, stating that the staff of the SEC was conducting a Section 8(e) examination with respect to this Form S-1 and that the Division of Corporate Finance would not take any further action on the Form S-1 while the examination was pending. We received subpoenas to produce documents dated December 14, 2016, and January 23, 2017, and a further subpoena for testimony and any supplemental production of documents dated June 5, 2017. The document requests were primarily in connection with this matter. We have complied with all document requests and the Company’s CEO will provide testimony when the SEC schedules such testimony, which we believe will be sometime before the end of September 2018.